Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model
Authors:
- Dorothee AbramowskiDADorothee Abramowski
- Matthias StaufenbielMSMatthias Staufenbiel
- Peter Paul De DeynPDPeter Paul De Deyn
- 15 January 2005
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 180 (1) , 177-190
Abstract
Rationale APP23 mice are a promising model of Alzheimer’s disease, expressing several histopathological, cognitive and behavioural hallmarks of the human condition. A valid animal model should respond to therapeutic interventions in an equivalent manner as human patients. Objectives To further validate the APP23 model, we examined whether cognitive deficits could be antagonised by donepezil, rivastigmine, galantamine or memantine, which are approved drugs for symptomatic treatment of dementia. Methods Animals were tested at an age at which untreated APP23 mice display severe deficits in visual–spatial learning. Four-month-old APP23 mice and control littermates were administered donepezil (0.3 or 0.6 mg kg−1), rivastigmine (0.5 or 1.0 mg kg−1), galantamine (1.25 or 2.5 mg kg−1), memantine (2 or 10 mg kg−1) or saline through daily i.p. injections. After 1 week of treatment, acquisition phase commenced, with daily treatment continuing during cognitive testing. Results All cholinesterase inhibitors reduced cognitive deficits with the following optimal daily doses: galantamine 1.25 mg kg−1, rivastigmine 0.5 mg kg−1 and donepezil 0.3 mg kg−1. Higher dosages often did not exert beneficial effects in accordance with inverted U-shaped dose–response curves described for cholinomimetics. Symptomatic efficacy of memantine on cognition was mild, with significant amelioration manifesting during probe trial. Conclusions This is the first study to simultaneously evaluate the efficacy of therapeutically relevant doses of these four compounds in one particular learning and memory paradigm, being the Morris water maze. The fact that symptomatic intervention was able to diminish cognitive impairment, substantially adds to the validity of the APP23 model as a valuable tool to evaluate future therapeutic approaches.Keywords
This publication has 90 references indexed in Scilit:
- Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse modelsNeurochemistry International, 2005
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Rodent spatial navigation: at the crossroads of cognition and movementNeuroscience & Biobehavioral Reviews, 2004
- Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase InhibitorThe Japanese Journal of Pharmacology, 2002
- Animal models of human disorders?general aspectsNeuroscience Research Communications, 2000
- Nicotinic System Involvement in Alzheimer??s and Parkinson??s DiseasesDrugs & Aging, 1997
- Maze procedures: the radial-arm and water maze comparedCognitive Brain Research, 1996
- d-cycloserine attenuates scopolamine-induced learning and memory deficits in ratsBehavioral and Neural Biology, 1993
- Neurochemical Substrates of Human Aging and DementiaPharmacopsychiatry, 1990
- Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivoLife Sciences, 1990